The proteasome inhibitor MG132 induces nuclear translocation of erythroid transcription factor Nrf2 and cyclooxygenase-2 expression in human vascular endothelial cells

Thrombosis Research

Volumn 122, Issue 6, 2008, Pages 820-825

  Sahni, Sanjeev K ^a,b   Rydkina, Elena ^a,b   Sahni, Abha ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b Thrombosis and Hemostasis Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYCLOOXYGENASE 2; PROTEASOME INHIBITOR; TRANSCRIPTION FACTOR NRF2;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR ENDOTHELIUM;

ACTIVE TRANSPORT, CELL NUCLEUS; CELL NUCLEUS; CELLS, CULTURED; CYCLOOXYGENASE 2; CYSTEINE PROTEINASE INHIBITORS; ENDOTHELIAL CELLS; HUMANS; LEUPEPTINS; NF-E2-RELATED FACTOR 2; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA, MESSENGER;

EID: 52049100130     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.01.011     Document Type: Article

References (32)

1. Goldberg A.L., Stein R., and Adams J. New insights into proteasome function: from archaebacteria to drug development. Chem Biol 2 (1995) 503-508
2. Liu S.F., and Malik A.B. NF-κB activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 290 (2006) L622-L645
3. Chauhan D., Hideshima T., and Anderson K.C. Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol 45 (2005) 465-476
4. Wente M.N., Eibl G., Reber H.A., Friess H., Buchler M.W., and Hines O.J. The proteasome inhibitor MG132 induces apoptosis in human pancreatic cancer cells. Oncol Rep 14 (2005) 1635-1638
5. Sun X., Gulyas M., Hjerpe A., and Dobra K. Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells. Cancer Lett 232 (2006) 161-169
6. Yang H., Chen D., Cui Q.C., Yuan X., and Dou Q.P. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 66 (2005) 4758-4765
7. Drexler H.C., Risau W., and Konerding M.A. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 14 (2000) 65-77
8. Peiretti F., Canault M., Bernot D., Bonardo B., Deprez-Beauclair P., Juhan-Vague I., et al. Proteasome inhibition activates the transport and the ectodomain shedding of TNF-a receptors in human endothelial cells. J Cell Sci 118 (2005) 1061-1070
9. Shibata T., Imaizumi T., Tamo W., Matsumiya T., Kumagai M., Cui X.F., et al. Proteasome inhibitor MG-132 enhances the expression of interleukin-6 in human umbilical vein endothelial cells: Involvement of MAP/ERK kinase. Immunol Cell Biol 80 (2002) 226-230
10. Shibata T., Imaizumi T., Matsumiya T., Tamo W., Hatakeyama M., Yoshida H., et al. Effect of MG132, a proteasome inhibitor, on the expression of growth related oncogene protein-a in human umbilical vein endothelial cells. Cytokine 24 (2003) 67-73
11. Petrucelli L., and Dawson T.M. Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system. Ann Med 36 (2004) 315-320
12. Yano M., Kanesaki Y., Koumoto Y., Inoue M., and Kido H. Chaperone activities of the 26S and 20S proteasome. Curr Protein Pept Sci 6 (2005) 197-203
13. Ding Q., Dimayuga E., and Keller J.N. Proteasome regulation of oxidative stress in aging and age-related diseases of the CNS. Antioxid Redox Signal 8 (2006) 163-172
14. Rojas A., Figueroa H., Morales M.A., and Re L. Facing up the ROS labyrinth-Where to go?. Curr Vasc Pharmacol 4 (2006) 277-289
15. Kobayashi A., Ohta T., and Yamamoto M. Unique function of the Nrf2-Keap1 pathway in the inducible expression of antioxidant and detoxifying enzymes. Methods Enzymol 378 (2004) 273-286
16. Sporn L.A., Sahni S.K., Lerner N.B., Marder V.J., Silverman D.J., Turpin L.C., et al. Rickettsia rickettsii infection of cultured human endothelial cells induces NF-κB activation. Infect Immun 65 (1997) 2786-2791
17. Clifton D.R., Goss R.A., Sahni S.K., van Antwerp D., Baggs R.B., Marder V.J., et al. NF-κB-dependent inhibition of apoptosis is essential for host cell survival during Rickettsia rickettsii infection. Proc Natl Acad Sci USA 95 (1998) 4646-4651
18. Sahni S.K., Van Antwerp D.J., Eremeeva M.E., Silverman D.J., Marder V.J., and Sporn L.A. Proteasome-independent activation of nuclear factor κB in cytoplasmic extracts from human endothelial cells by Rickettsia rickettsii. Infect Immun 66 (1998) 1827-1833
19. Joshi S.G., Francis C.W., Silverman D.J., and Sahni S.K. NF-κB activation suppresses host cell apoptosis during Rickettsia rickettsii infection via regulatory effects on intracellular localization or levels of apoptogenic and anti-apoptotic proteins. FEMS Microbiol Lett 234 (2004) 333-341
20. Rydkina E., Sahni A., Baggs R.B., Silverman D.J., and Sahni S.K. Infection of human endothelial cells with spotted Fever group rickettsiae stimulates cyclooxygenase 2 expression and release of vasoactive prostaglandins. Infect Immun 74 (2006) 5067-5074
21. Davidge E. Prostaglandin H synthase and vascular function. Circ Res 89 (2001) 650-660
22. Parry S.T., Martin T., Felts K.A., and Cobb R.R. IL-1β-induced monocyte chemoattractant protein-1 gene expression in endothelial cells is blocked by proteasome inhibitors. Arterioscler Thromb Vasc Biol 18 (1998) 934-940
23. Kalogeris T.J., Laroux F.S., Cockrell A., Ichikawa H., Okayama N., Phifer T.J., et al. Effect of selective proteasome inhibitors on TNF-induced activation of primary and transformed endothelial cells. Am J Physiol 276 (1999) C856-C864
24. Hipp M.S., Urbich C., Mayer P., Wischhusen J., Weller M., Kracht M., et al. Proteasome inhibition leads to NF-κB-independent IL-8 transactivation in human endothelial cells through induction of AP-1. Eur J Immunol 32 (2002) 2208-2217
25. Woo K.J., Park J.W., and Kwon T.K. Proteasome inhibitor-induced cyclooxygenase-2 expression in Raw264.7 cells is potentiated by inhibition of c-Jun N-terminal kinase activation. Biochem Biophys Res Commun 342 (2006) 1334-1340
26. Chen X.L., Varner S.E., Rao A.S., Grey J.Y., Thomas S., Cook C.K., et al. Laminar flow induction of antioxidant response element-mediated genes in endothelial cells, A novel anti-inflammatory mechanism. J Biol Chem 278 (2003) 703-711
27. Chen X.L., Dodd G., Thomas S., Zhang X., Wasserman M.A., Rovin B.H., et al. Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am J Physiol Heart Circ Physiol 290 (2006) H1862-H1870
28. Buckley B.J., Marshall Z.M., and Whorton A.R. Nitric oxide stimulates Nrf2 nuclear translocation in vascular endothelium. Biochem Biophys Res Commun 307 (2003) 973-979
29. Itoh K., Wakabayashi N., Katoh Y., Ishii T., O'Connor T., and Yamamoto M. Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes Cells 8 (2003) 379-391
30. Motohashi H., and Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 10 (2004) 549-557
31. Doll D., Sarikas A., Krajcik R., and Zolk O. Proteomic expression analysis of cardiomyocytes subjected to proteasome inhibition. Biochem Biophys Res Commun 353 (2007) 436-442
32. Veschini L., Belloni D., Foglieni C., Cangi M.G., Ferrarini M., Caligaris-Cappio F., et al. Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib. Blood 109 (2007) 2565-2570